Skip to main content
. 2011 Dec 14;44(3):191–201. doi: 10.3858/emm.2012.44.3.014

Figure 1.

Figure 1

Syringaresinol causes relaxation in aortic rings pre-contracted with PhE. (A) Syringaresinol (SY)-induced relaxation was determined in endothelium-intact (closed circle) and -denuded (open circle) aortic rings pre-contracted with PhE. Data are the mean ± SD (n ≥ 8). **P < 0.01 versus endothelium-denuded aortic rings. (B) Syringaresinol-induced relaxation was determined in endothelium-intact (closed circle and rectangle) and -denuded (open circle) aortic rings in the presence (rectangle) or absence (circles) of 1 mM L-NMA for 40 min. Data are the mean ± SD (n ≥ 8). *P < 0.05 and **P < 0.01 versus endothelium-denuded aortic rings. #P < 0.01 versus endothelium-intact aortic rings treated with SY anole. (C) The level of cGMP was determined in the tissue homogenates from endothelium-intact aortic rings, which were incubated with 30 µM syringaresinol in the presence or absence of 1 mM L-NMA for 40 min. Data are the mean ± SD (n ≥ 5). **P < 0.01 versus untreated control. #P < 0.01 versus endothelium-intact aortic rings treated with SY. (D) Vascular relaxation was determined in NOS-deficient aortic rings treated with 30 µM syringaresinol for 40 min following pre-contraction with PhE. Data shown are the mean ± SD (n ≥ 8). **P < 0.01 versus control. (E) Aortic rings were treated with 30 µM syringaresinol and cGMP level was determined as shown in (C). Data shown are the mean ± SD (n ≥ 5). **P < 0.01 versus untreated control.